Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Boehringer is paying $50M upfront for an early-stage IPF asset as it scouts a follow-up to its blockbuster Ofev franchise, betting on a novel autotaxin…
Bridge regains all global rights to BBT-877 after Boehringer requests additional toxicity testing and the parties cannot align on a development path forward.
Boehringer Ingelheim and Bridge Biotherapeutics mutually terminated the BBT-877 collaboration after preclinical toxicity findings; rights revert to Bridge,…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Boehringer Ingelheim entered a global collaboration and license agreement for Bridge Biotherapeutics' Phase 1 autotaxin inhibitor BBT-877 in fibrosing interstitial lung diseases including IPF. Bridge received approximately EUR 45M ($50M) in upfront/near-term payments and is eligible for up to EUR 1.1B+ ($1.18B) in milestones plus tiered up-to-double-digit royalties. Deal terminated in late 2020 after BBT-877 mutagenicity findings.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. (this deal) | 2019 | $1.2B | — |
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) | 2011 | — | 77 |
| Boehringer Ingelheim GmbH / NBE Therapeutics | 2020 | $1.5B | 28 |
| Boehringer Ingelheim GmbH / AMAL Therapeutics SA | 2019 | $366M | — |
| Boehringer Ingelheim GmbH / NBE-Therapeutics AG | 2020 | $1.4B | — |
| Boehringer Ingelheim GmbH / Yuhan Corporation | 2019 | $870M | — |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Boehringer Ingelheim GmbH deals · Respiratory deals